Financial Performance - Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion, despite an impairment loss of DKK 5.7 billion related to ocedurenone [1] - Net sales grew by 24% in Danish kroner (25% at CER) to DKK 133.4 billion, with net profit increasing by 16% to DKK 45.5 billion [3] - Diluted earnings per share rose by 17% to DKK 10.17 [3] Regional and Product Sales - North America Operations sales increased by 36% in Danish kroner (36% at CER), driven by gross-to-net sales adjustments in the US [2] - International Operations sales grew by 9% in Danish kroner (11% at CER) [2] - Diabetes and Obesity care sales surged by 26% in Danish kroner (27% at CER) to DKK 125.0 billion, with GLP-1 diabetes sales up 32% and Obesity care sales up 37% to DKK 24.9 billion [2] - Rare disease sales declined by 4% in Danish kroner (3% at CER) [2] Research and Development - The phase 3 FRONTIER 2 trial for Mim8 demonstrated superior reduction of treated bleeding episodes in haemophilia A patients [2] - The ocedurenone CLARION-CKD phase 3 trial was stopped due to failure to meet the primary endpoint [2] - The FDA issued a Complete Response Letter for insulin icodec in July 2024 [2] - A positive CHMP opinion was received for updating the Wegovy® label to reflect cardiovascular risk reduction in the EU [2] Outlook - Sales growth for 2024 is now expected to be 22-28% at CER, with operating profit growth projected at 20-28% at CER [2] - Growth reported in Danish kroner is expected to be 1 percentage point lower than CER growth for both sales and operating profit [2] Leadership Commentary - The CEO highlighted strong sales growth driven by increased demand for GLP-1-based diabetes and obesity treatments, as well as positive R&D developments including Mim8 trial results and the Wegovy® label extension recommendation [4]

It's not hard to envision how all three of these stocks can deliver exceptional growth.What are the best stocks? Usually, the ones that have clear paths to success.Three Motley Fool contributors have identified what they believe are unstoppable stocks to buy in August. And they all happen to be biotech and pharma companies. Here's why they picked Novo Nordisk (NVO -3.75%), Vertex Pharmaceuticals (VRTX -2.24%), and Viking Therapeutics (VKTX -2.93%).There's still plenty more room to growDavid Jagielski (Novo ...

Novo Nordisk (NVO) ended the recent trading session at $128.05, demonstrating a +1.04% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.12%, while the tech-heavy Nasdaq appreciated by 0.07%.The drugmaker's shares have seen a decrease of 11.22% over the last month, not keeping up with the Medical sector's gain of 0.48% and the S&P 500's loss of 0.21%.Market participants will be closely following t ...

Core Viewpoint - Novo Nordisk has initiated a share repurchase program with a total value of up to DKK 20 billion, which will be executed over a 12-month period starting from February 6, 2024 [1][3]. Share Repurchase Program Details - The program initiated on May 6, 2024, includes a repurchase of B shares for an amount up to DKK 2.2 billion from May 7, 2024, to August 5, 2024 [1]. - As of July 26, 2024, Novo Nordisk has repurchased a total of 10,820,537 B shares at an average price of DKK 878.72 per share, amounting to a total transaction value of DKK 9,508,271,105 [3]. Transaction Summary - The accumulated number of B shares repurchased as of the last announcement is 1,884,787, with a total transaction value of DKK 1,799,046,117 [2]. - Specific transactions from July 22 to July 26, 2024, include: - July 22: 39,000 shares at an average price of DKK 909.36, total value DKK 35,465,111 - July 23: 41,000 shares at an average price of DKK 918.79, total value DKK 37,670,272 - July 24: 41,000 shares at an average price of DKK 909.74, total value DKK 37,299,164 - July 25: 40,000 shares at an average price of DKK 885.45, total value DKK 35,417,923 - July 26: 40,500 shares at an average price of DKK 879.94, total value DKK 35,637,745 [2]. Treasury Shares - Following the transactions, Novo Nordisk holds a total of 12,186,327 B shares as treasury shares, representing 0.3% of the total share capital [3]. - The total number of A and B shares in the company is 4,465,000,000, including treasury shares [3]. Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4]. - The company employs approximately 66,000 people across 80 countries and markets its products in around 170 countries [4]. - Novo Nordisk's B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange [4].

Ozempic could pile up a lot more indications in the years ahead.Novo Nordisk (NVO -0.88%) has become one of the most valuable healthcare stocks in the world due in large part to Ozempic, its diabetes drug that has also been effective in helping people lose weight. One challenge for investors and analysts, however, is predicting just how much revenue it could bring in at its peak. As new studies emerge involving the drug, there are new possible benefits uncovered relating to the use of Ozempic.Recently, ther ...

The company should maintain its lead in this growing area.Novo Nordisk (NVO -0.88%) is under attack. Although the Denmark-based drugmaker is a pioneer and leader in the GLP-1 diabetes and weight loss drug markets, countless companies are trying to steal its lunch. It's no wonder: Ozempic, a diabetes medicine, and Wegovy, a weight loss therapy with the same active ingredient, have both seen incredible success. Challengers were bound to rise, eventually. However, Novo Nordisk is also working on potential succ ...

Novo Nordisk (NVO) is slated to report second-quarter 2024 results on Aug 7, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $9.91 billion, while the same for earnings is pinned at 76 cents per share.In the past 30 days, the estimates for Novo Nordisk’s 2024 earnings per share (EPS) deteriorated from $3.41 to $3.38. During the same time frame, the forecast for the company’s 2025 EPS has improved from $4.30 to $4.35.Image Source: Zacks I ...

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults.The Danish pharmaceutical giant on Thursday said that the European Medical Agency had adopted a "positive opinion" on the label expansion after reviewing the outcomes of a closely watched SELECT trial, opening t ...

LONDON — The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes.The new approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) makes the Danish pharmaceutical giant's GLP-1 obesity drug the first in the country to be prescribed for prevention of cardiovascular events in people with obesity.It follows similar label expansion by the U.S. Foo ...

Loading...Loading...The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against including the company’s popular weight-loss drug, Wegovy, in the basic insurance coverage.The institute’s recommendation, delivered on Tuesday, cited insufficient clarity on whether Wegovy’s health benefits justify its costs.Related: Bernie Sanders Targets High Prices of Ozempic and Wegovy In US.Al ...